Advancement in Equine Research Award
At Boehringer Ingelheim Vetmedica, Inc., we're furthering our commitment to research efforts to ensure that we continue to learn more about equine diseases.
Scientists, researchers, practicing veterinarians, animal health companies, and horse owners have long been dedicated to improving the health of the horse. Yet the need for more knowledge in regards to disease prevention, lameness and general wellness still exists.
At Boehringer Ingelheim Vetmedica, Inc., we're furthering our commitment to research efforts to ensure that we continue to learn more about equine diseases.
We are pleased to announce the first year of our Annual Boehringer Ingelheim Advancement in Equine Research Award Program. The deadline for submissions is September 1, 2011.
The 2011 Advancement in Equine Research Awards recipients will be announced at the American Association of Equine Practitioners Conference in San Antonio, Texas.
The BIVI Equine Research Award will focus on one specific equine disease area each year. For 2011 the equine disease of focus is Equine Rhinitis Virus (ERV). Specifically, four areas of interest within ERV have been identified:
- Pathophysiology of ERV In the horse.
- Incidence and implications of co-infection with ERV and other equine respiratory pathogens.,
- Incidence of ERV related to geographical location and equine discipline.
- Acute/chronic effects of ERV on the lower airway disease in the horse.
Boehringer Ingelheim will provide three $25,000 awards to the winning proposals for Rhinitis research in the US and Canada. Candidates include graduate students, academic researchers, company or private researchers, and practicing veterinarians. Winning proposals will be selected by an independent review board.
Once the three winning year-long research projects are completed and submitted for peer review, the Equine Research Review Board will conduct a second evaluation. Upon acceptance for publication of his or her findings, the first place award recipient will receive an additional U.S. $5,000; second place, $3,000; and third place, $1,000.
Our independent Equine Research Review Board members look forward to reviewing your proposal.
Submit Your Proposal To:
-
The Advancement in Equine Research Award
Boehringer Ingelheim Vetmedica, Inc.
Attn: Marion Tittle
5506 Corporate Dr., Suite 1600
St. Joseph, MO 64507-7752
Mark the envelope “The Advancement in Equine Research Award”
About Boehringer Ingelheim Vetmedica
The Boehringer Ingelheim group is one of the world’s 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 145 affiliates and more than 42,000 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel products of high therapeutic value for human and veterinary medicine.
For Boehringer Ingelheim—and its employees—carrying a good share of social responsibility is an important component in its business culture. Both global commitments in social projects and properly caring for all its employees are included. Respect, equal opportunity, and the balance of career and family life form the basis for mutual cooperation. And, environmental protection and sustainability are always the main focus during any of Boehringer Ingelheim’s undertakings.
In 2010, Boehringer Ingelheim posted net sales of approximately $16.7 billion (about 12.6 billion euro) while spending almost 24% of net sales in its largest business segment, Prescription Medicines, on research and development.
For more information, please visit http://us.boehringer-ingelheim.com and follow us on Twitter at http://twitter.com/boehringerus.
Contact Us
-
The Advancement in Equine Research Award
Boehringer Ingelheim Vetmedica, Inc.
Attn: Marion Tittle
5506 Corporate Dr., Suite 1600
St. Joseph, MO 64507-7752
